Skip Navigation


Annals of Oncology Advance Access originally published online on August 10, 2005
Annals of Oncology 2005 16(10):1683-1687; doi:10.1093/annonc/mdi323
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/10/1683    most recent
mdi323v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nogová, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nogová, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)

L. Nogová1,*, T. Reineke1, H. T. Eich2, A. Josting1, H. K. Müller-Hermelink4, K. Wingbermühle1, C. Brillant1, A. Gossmann3, J. Oertel5, M. V. Bollen6, R.-P. Müller2, V. Diehl1, A. Engert1 for the GHSG

1 Clinic I for Internal Medicine, 2 Clinic of Radiotherapy and 3 Department of Radiology of University Hospital Cologne; 4 Insitut for Pathology of University Wuerzburg; 5 Campus Virchow Klinikum, Berlin; 6 University Hospital Heidelberg, Heidelberg, Germany and the German Hodgkin Lymphoma Study Group (GHSG)

* Correspondence to: Dr L. Nogová, First Department of Internal Medicine, University Hospital Cologne, Kerpenerstr. 62, 50924 Cologne, Germany. Tel: +49-221-478-6033; Fax: +49-221-478-6459; E-mail: lucia.nogova{at}uk-koeln.de

Background: Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL) remains unclear. We thus reviewed all LPHL cases registered in the database of the German Hodgkin Study Group (GHSG) and compared the different treatment approaches, such as extended field (EF), involved field (IF) radiation and combined modality (CM) treatment for LPHL stage IA patients.

Patients and methods: One hundred and thirty-one patients with LPHL in clinical stage IA without risk factors were analyzed. Forty-five patients were treated with EF radiotherapy, 45 patients with IF radiation and 41 patients received CM treatment. The median follow-up was 78 months in the EF group, 40 months after CM and 17 months after IF, respectively.

Results: A total of 129 patients achieved complete remission (CR and CRu): 98% after EF radiotherapy, 100% after IF radiation and 95% after CM. With a median follow-up of 43 months there were 5% relapses and only three patients died. Toxicity of treatment was generally mild with most events observed after CM.

Conclusion: In terms of remission induction IF radiotherapy for stage IA LPHL patients is as effective as EF or CM treatment. However, longer follow-up is needed before final conclusion as the optimal therapy.

Key words: combined modality treatment, extended field radiotherapy, involved field radiotherapy, lymphocyte-predominant Hodgkin's lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. Nogova, T. Reineke, C. Brillant, M. Sieniawski, T. Rudiger, A. Josting, H. Bredenfeld, R. Skripnitchenko, R.-P. Muller, H.-K. Muller-Hermelink, et al.
Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
J. Clin. Oncol., January 20, 2008; 26(3): 434 - 439.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al.
Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial
J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
L. Nogova, T. Rudiger, and A. Engert
Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 266 - 272.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.